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What’s Known on This Subject
For pediatric candidates for epilepsy surgery, MCD is the predominant etiology. Never-
theless, epilepsy surgery is still challenging because of seizure relapse and morbidity.
The KD has been used as a safe and effective alternative therapy for intractable child-
hood epilepsy.
What This Study Adds
Most series published have included only a small number of patients with focal MCD.
This study evaluates the efﬁcacy of the KD and the long-term prognoses after its suc-
cessful completion in patients with intractable childhood epilepsy from focal MCD.
ABSTRACT
OBJECTIVE.We evaluated the efficacy and long-term outcome of the ketogenic diet in
patients with intractable childhood epilepsy as a result of focal malformation of
cortical development.
METHODS.A retrospective analysis evaluated seizure outcomes of 47 patients who had
intractable epilepsy from (and) surgically remediable focal malformation of cortical
development and were first treated with the classic ketogenic diet, involving the 4:1
lipid/nonlipid ratio. The long-term prognosis of 21 patients, who became seizure-free
3 months after the ketogenic diet, was followed up with that of 22 patients who
eventually underwent epilepsy surgery.
RESULTS. Three months after diet initiation, 29 (61.7%) patients showed a reduction in
seizure frequency of 50%, including 21 (44.7%) who became seizure-free. Of the
21 patients with complete seizure control at 3 months, 16 (76.2%) successfully
completed the diet for 2 years without relapse, and 10 (47.6%) have remained
seizure-free after cessation of the diet (mean follow-up for 3 years and 10 months),
including 1 patient who remained seizure-free with additional medication after a
relapse. Of the 22 patients who underwent epilepsy surgery, a seizure-free outcome
was obtained for 13 (59.1%).
CONCLUSIONS. The ketogenic diet should be considered to be an additional option even
in patients with focal malformation of cortical development, and long-term seizure-
free outcome can be expected for patients who become seizure-free 3 months after
the diet. Pediatrics 2008;122:e330–e333
THE CAUSES OF intractable childhood epilepsy are quite variable, and modernimaging techniques have improved the detection of malformation of cortical
development (MCD), which frequently evolves to secondary generalized epileptic encephalopathy.1–3 In pedi-
atric candidates for epilepsy surgery, focal MCD is the predominant etiology.4 Surgical treatment of highly
selected patients with a well-demarcated epileptic focus can provide complete seizure control and dramatic
catch-up in developmental progress, without serious complications.5,6 Nevertheless, despite such gratifying
results from epilepsy surgery, surgical intervention in most patients is still challenging because of the potential
risks of seizure relapse and functional morbidity.7
Since the resurgence of the ketogenic diet (KD) (a high-fat, adequate-protein, low-carbohydrate diet) in the
mid-1990s, it has been used extensively and recognized as a safe and effective alternative therapy for intractable
childhood epilepsy.8 Patients with MCD, who have a more immature cerebral cortex, may respond particularly well
to the diet.9 Most series published to date, however, have included only a small number of patients with focal MCD
and were limited by an absence of data describing the long-term prognosis after completion of the diet therapy.10,11
We aimed to evaluate the efficacy of the KD and the long-term prognosis after its successful completion and to
determine the role of the diet in patients with intractable childhood epilepsy from focal MCD.
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METHODS
The patients in this study were 47 patients who were
treated for epilepsy at the 2 epilepsy centers at Yonsei
University and Inje University (Seoul, Korea). These
were patients who had been experiencing 4 seizures
per month, with seizures uncontrolled by3 antiepilep-
tic drugs. In all patients, focal MCD related to the intrac-
table seizures had been discovered by high-resolution
MRI, and in 22 patients, the diagnosis was later con-
firmed by histopathologic examinations after epilepsy
surgery. MRI scans were obtained with a 1.5-T magnetic
resonance system (Marconi, Cleveland, OH), using spin-
echo T1-weighted images (T1WI, repetition time [TR]/
echo time [TE] 476/16 milliseconds) and fast spin-echo
T2-weighted images (T2WI, TR/TE 4000/105 millisec-
onds). Additional high-resolution MRIs using three-di-
mensional RF spoiled Fourier acquired steady state with
thin (1.6- to 2.0-mm) thickness (TR/TE 30/4.47 milli-
seconds, flip angle 30°), and fast inversion recovery for
myelin suppression with thin thickness (TR/TE/inver-
sion time 6500/54/200 milliseconds) were also obtained.
MCD findings were confirmed by 2 independent neuro-
radiologists who were blinded to the clinical and elec-
troencephalogram information. Histopathologic exami-
nations followed the Palmini and Luders classification12:
type 1 (A  isolated architectural abnormalities, B 
plus giant or immature but not dysmorphic neurons),
and type 2 (A  architectural abnormalities with dys-
morphic neurons but without balloon cells, B  with
balloon cells). In addition, mild cortical dysplasia was
defined as ectopically placed neurons in or adjacent to
the first cortical layer or microscopic neuronal heteroto-
pia outside the layer.
Surgical treatment had been considered for the pa-
tients, but the caregivers/parents agreed to prioritize the
trial of the KD. All patients received the classic KD as an
add-on treatment with a lipid/nonlipid ratio of 4:1 with-
out initial fasting and fluid restriction. We previously
published a detailed protocol for the classic KD, sched-
uled assessments for evaluating complications, and used
the method to obtain data, as described in previous
reports.13,14 We observed initial outcomes after 3 months
on the KD and decided whether the diet should be
continued. The KD was maintained for 2 years and
subsequently discontinued with a gradual decrease in
the ratio for 4 to 6 months. The patients whose seizures
were not completely controlled during the KD or who
had recurrences after discontinuing the KD underwent
evaluation for surgical treatment. All patients were fol-
lowed for at least 12 months after discontinuation or
completion of the KD.
RESULTS
Patient Characteristics
Of the 47 patients (29 male, 18 female), 15 (31.9%) had
a diagnosis of infantile spasms, 17 (36.2%) of Lennox-
Gastaut syndrome, and 15 (31.9%) of partial seizures.
Patients experienced their first seizure at a mean  SD
age of 18.6  28.7 months. The mean  SD age of the
patients at the beginning of the diet was 47.2  33.7
months. The mean  SD duration of the patients’ epi-
lepsy before the KD was 28.6  24.2 months.
MRI findings included focal cortical thickening, blur-
ring at the gray–white matter junction, dysgyria, and
focal T2-prolongation of subcortical white matter in 42
patients; focal nodular heterotopia (1 patient); schizen-
cephaly (1 patient); and pachygyria (1 patient). Two
patients had hemimegalencephaly. Localization of the
MCD was in the frontal lobe in 25 (53.2%) patients, the
parieto-occipital lobes in 8 (17.1%), the temporal lobe in
5 (10.6%), and multilobar areas (involving 1 lobe in a
single hemisphere) in 9 (19.1%) patients. The detailed
clinical profiles and MRI findings are summarized in
Table 1.
Efﬁcacy and Long-Term Outcomes of the KD
Three months after initiating the diet, 29 (61.7%) pa-
tients remained on the diet and showed a 50% reduc-
tion in seizure frequency, including 21 (44.7%) who
became seizure-free. Among the 21 patients with sei-
zure-free outcomes at 3 months, 16 (76.2%) successfully
completed the diet for 2 years without seizure relapse.
Furthermore, 9 (42.9%) of them have remained seizure-
free over a mean follow-up period of 3 years and 10
months (range: 13 months to 7 years) after successful
completion of the diet. Of the 7 patients who showed
relapse seizures after completion of the diet, 1 patient
became seizure-free with additional medication, 3 were
lost to follow-up, and 3 patients ultimately underwent
epilepsy surgery. In addition, of the 21 patients who
remained seizure-free 3 months after diet initiation, 10
(47.6%) showed seizure-free outcomes even after com-
pletion of the KD. A schematic diagram of the long-term
outcomes in these 47 patients is shown in Fig 1.
During administration of the KD, 2 patients stopped
the diet as a result of hemorrhagic gastritis. Despite diet
TABLE 1 Clinical Proﬁles of Patients With Intractable Childhood
Epilepsy and Focal MCD (N 47)
Parameter Value
Male/female, n/n 29/18
Age on seizure onset, mean SD, mo 18.6 28.7
Age on beginning the KD, mean SD, mo 47.2 33.7
Duration from seizure onset to the KD, mean SD, mo 28.6 24.2
Epilepsy classiﬁcation, n (%)
Infantile spasms 15 (31.9)
Lennox-Gastaut syndrome 17 (36.2)
Partial epilepsy 15 (31.9)
Localizations of MCD, n (%)
Frontal 25 (53.2)
Temporal 5 (10.6)
Parieto-occipital 8 (17.1)
Multilobar 9 (19.1)
MRI ﬁndings, n (%)
Focal cortical dysplasiaa 42 (89.4)
Focal nodular heterotopia 1 (2.1)
Schizencephaly 1 (2.1)
Pachygyria 1 (2.1)
Hemimegalencephaly 2 (4.3)
a MRI ﬁndings of focal cortical dysplasia, consisting of focal cortical thickening with or without
blurring at the gray–white matter junction/focal T2 prolongation of subcortical white matter.
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intolerance in 5 patients, a reduction in seizure fre-
quency of 50% was observed.
Outcomes of Surgical Treatment
Eventually, 22 patients, including 19 in whom seizures
were not controlled completely during the KD and 3
patients who had relapsed seizures after successful com-
pletion of the KD, underwent surgical treatments. Only
2 patients had temporal lobe lesions; others had extra-
temporal (14 patients), multilobar (3 patients), or hemi-
spheric (3 patients) lesions.
Of 22 patients who underwent epilepsy surgery, 13
(59.1%) obtained Engel class I outcomes, 5 (22.7%)
obtained Engel class II outcomes, 2 (9.1%) obtained
Engel class III outcomes, and 2 (9.1%) had no improve-
ment during the mean  SD follow-up period of 31.5 
26.2 months after epilepsy surgery (range: 8 months to 7
years). In the 22 patients, tissue pathologies were clas-
sified as MCD type 1 or type 2 in 18 patients and mild
cortical dysplasia in 4 (Table 2). After surgery, no major
complications occurred in those who had regional resec-
tions, but contralateral hemiparesis was seen in 3 pa-
tients who had hemispherec(o)tomy.
DISCUSSION
This study describes the experience of the KD in patients
with intractable epilepsy and surgically remediable focal
MCD. At 3 months after diet initiation, 21 (44.7%)
patients became seizure-free. Sixteen (34%) patients
successfully completed the diet, and 9 (19.1%) showed
seizure-free outcomes even after completion of diet
therapy to the time of the final follow-up (range: 13
months to 7 years). Of 21 patients who were seizure-free
at 3 months after diet initiation, 10 (47.6%) remained
seizure-free even after completion of diet therapy, in-
cluding 1 patient who remained seizure-free with
additional medication after a relapse.
Outcomes in our patients with focal MCD were supe-
rior to those of large prospective and retrospective stud-
ies of the conventional KD in patients with seizures of
various causes.10,15 An Italian group treated 7 patients
(mean age: 8.2 years; range: 2.8–16.1) who had diffuse
migrational disorders; at 9 months after the introduction
of the diet, 4 of them experienced a decrease in seizure
frequency between 50% and 90%.16 Coppola et al11 and
Than et al9 suggested that patients with MCD may re-
spond particularly well to the diet. Biological evidence
also supports good responses to the KD in patients with
MCD. In suckling rats, the more immature the cerebral
cortex is, the more it uses ketone bodies, instead of
glucose, as an energetic substrate.17,18 Most patients in
this study had cortical dysplasia with variable extent and
severity, and we could not differentiate the efficacy of
the diet therapy according to specific types of MCD. We
were also unable to find a significant difference in sei-
zure outcomes in specific types of lesions.
Epilepsy surgery, whenever possible, is used in the
treatment of intractable childhood epilepsy with focal
MCD but does not always guarantee a favorable result.7
In pediatric series, predominant surgical interventions
are extratemporal or multilobar resections or hemi-
spherec(o)tomies.4 Seizure-free outcomes are less com-
mon in these patients than in those who undergo tem-
poral resections.7 The Cleveland Clinic’s pediatric study
FIGURE 1
Flow diagram of short-term and long-term efﬁcacy of the KD in
intractable childhood epilepsy with focal MCD (N 47).
TABLE 2 Surgical Treatment Outcomes of Patients With Focal MCD
(n 22)
Parameter n (%)
Surgical approach
Temporal lobe resection 2 (9.1)
Extratemporal resection 14 (63.6)
Multilobar resection 3 (13.6)
Hemispherec(o)tomy 3 (13.6)
Engel classiﬁcation (follow-up at 31.5 26.2 mo)
Seizure free (class I) 13 (59.1)
Rare seizure (class II) 5 (22.7)
Worthwhile reduction (class III) 2 (9.1)
No improvement (class IV) 2 (9.1)
Pathologic diagnosis
MCD type 1 or 2 18 (81.8)
Mild cortical dysplasia 4 (18.2)
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reported seizure-free outcomes in 54% of patients who
had extratemporal or multilobar resection and in 78% of
those who underwent temporal resections; results after
hemispherectomy were intermediate (68%).4 In our pa-
tients, of the 20 who had extratemporal or multilobar
resection or hemispherectomy, 12 (60%) patients ob-
tained Engel class I outcomes, a result similar to that of
the Cleveland Clinic report.
In the administration of the KD, various complica-
tions occurred, but most were transient and could easily
be managed by conservative treatments.13,19 Even serious
complications could be resolved after stopping the diet.13
Contrary to the complications of diet therapy, we expe-
rienced sustained hemiparesis in 3 patients who had
hemispherec(o)tomy. Because of the potential risks of
sustained functional morbidity, surgical intervention is
still challenging in most patients.
Twenty-seven (56%) of the patients in this study
started the KD at an age younger than 36 months (the
most compatible age for the KD). Seizure outcomes be-
tween younger and older children were similar, and the
compliance to the KD was far better in younger children.
Recent articles have demonstrated that considering its
safety and efficacy, the early use of the KD seems to be
a reasonable choice.20,21 Successful surgical treatment of
infants or younger children with focal MCD can provide
complete seizure control and restore developmental
progress as a result of the plasticity of the young brain.5,6
Nevertheless, despite the gratifying results of early sur-
gery, potential risks, such as hemodynamic instability,
should be carefully considered in these young pa-
tients.7,22
CONCLUSIONS
Of the 47 patients in this study, in the 22 patients who
underwent epilepsy surgery, 13 became seizure-free. In
addition, by virtue of the KD, an additional 10 patients
obtained seizure-free outcomes without epilepsy sur-
gery. Resection of the focal MCD, if possible, remains the
current treatment of choice in intractable epilepsy. Con-
versely, our results suggest that intractable childhood
epilepsy with surgically remediable focal MCD may also
respond favorably to the KD, and long-term seizure-free
outcome can be expected especially for patients who
become seizure-free at 3 months after the diet. Conclu-
sively, the KD should be considered as early as possible
and integrated with epilepsy surgery as part of a thera-
peutic strategy against refractory epilepsy as a result of
focal MCDs.
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